share_log

T2 Biosystems | SC 13G: Statement of acquisition of beneficial ownership by individuals-JACOB SAFIER(7.1%),NEW DIMENSIONS TRADING LTD.(7.1%)

T2 Biosystems | SC 13G: Statement of acquisition of beneficial ownership by individuals

T2 Biosystems | SC 13G:超过5%持股股东披露文件
美股SEC公告 ·  2024/03/12 06:13

Moomoo AI 已提取核心信息

On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier regarding their holdings in T2 Biosystems, Inc. The Schedule 13G filing indicates that New Dimensions Trading Ltd., a company organized under the laws of the Cayman Islands, and Jacob Safier, a United States citizen, collectively own 350,000 shares of T2 Biosystems' common stock, which represents 7.1% of the company's class of securities. This level of ownership triggers the requirement for the Schedule 13G filing under SEC rules. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of T2 Biosystems, nor were they held in connection with any transaction having that purpose or effect. The filing was signed and dated March 11, 2024, by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, confirming the accuracy of the information provided.
On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier regarding their holdings in T2 Biosystems, Inc. The Schedule 13G filing indicates that New Dimensions Trading Ltd., a company organized under the laws of the Cayman Islands, and Jacob Safier, a United States citizen, collectively own 350,000 shares of T2 Biosystems' common stock, which represents 7.1% of the company's class of securities. This level of ownership triggers the requirement for the Schedule 13G filing under SEC rules. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of T2 Biosystems, nor were they held in connection with any transaction having that purpose or effect. The filing was signed and dated March 11, 2024, by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, confirming the accuracy of the information provided.
2024年2月20日,New Dimensions Trading Ltd.和Jacob Safier就其持有的T2 Biosystems, Inc.向美国证券交易委员会(SEC)提交了一份重要文件。附表13G文件显示,根据开曼群岛法律组建的公司新维度贸易有限公司和美国公民雅各布·萨菲尔共拥有T2 Biosystems公司35万股普通股,占7.1% 该公司的证券类别。这种所有权级别触发了美国证券交易委员会规则对附表13G申报的要求。该文件称,收购这些股份不是为了改变或影响T2 Biosystems的控制权,也不是与任何具有该目的或效果的交易有关而持有的。该文件由新维度贸易有限公司董事查娜·爱德斯坦和雅各布·萨菲尔于2024年3月11日签署并注明日期,证实了所提供信息的准确性。
2024年2月20日,New Dimensions Trading Ltd.和Jacob Safier就其持有的T2 Biosystems, Inc.向美国证券交易委员会(SEC)提交了一份重要文件。附表13G文件显示,根据开曼群岛法律组建的公司新维度贸易有限公司和美国公民雅各布·萨菲尔共拥有T2 Biosystems公司35万股普通股,占7.1% 该公司的证券类别。这种所有权级别触发了美国证券交易委员会规则对附表13G申报的要求。该文件称,收购这些股份不是为了改变或影响T2 Biosystems的控制权,也不是与任何具有该目的或效果的交易有关而持有的。该文件由新维度贸易有限公司董事查娜·爱德斯坦和雅各布·萨菲尔于2024年3月11日签署并注明日期,证实了所提供信息的准确性。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息